Anika Rotator-Cuff Treatment May Launch in 1Q Following Final FDA Approval
17 Agosto 2023 - 8:57PM
Dow Jones News
By Adam L. Cataldo
Anika Therapeutics expects to release its treatment for
rotator-cuff repairs in early 2024 after it received final 510(k)
clearance from the U.S. Food and Drug Administration.
The Integrity Implant System is designed to promote healing by
augmenting an injured tendon following rotator-cuff-repair
procedures, the company said.
Based in Bedford, Mass., Anika Therapeutics is a
joint-preservation company focused on early intervention
orthopedics.
A limited market release of the system in the U.S. is expected
to begin in the first quarter, the company said. A wider release in
the U.S. and expansion into international markets will follow.
The U.S. market for rotator-cuff augmentation is estimated at
$150 million and is growing at a nearly 7% compound annual growth
rate over the next five years, the company said.
Write to Adam Cataldo at adam.cataldo@wsj.com.
(END) Dow Jones Newswires
August 17, 2023 19:42 ET (23:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Anika Therapeutics (NASDAQ:ANIK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Anika Therapeutics (NASDAQ:ANIK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024